Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 1
1951 1
1953 1
1955 4
1956 3
1957 2
1958 3
1959 4
1962 1
1965 5
1966 14
1967 22
1968 21
1969 25
1970 34
1971 35
1972 47
1973 59
1974 56
1975 54
1976 47
1977 51
1978 71
1979 67
1980 71
1981 64
1982 92
1983 99
1984 111
1985 107
1986 136
1987 125
1988 108
1989 129
1990 162
1991 166
1992 141
1993 148
1994 139
1995 137
1996 119
1997 165
1998 168
1999 161
2000 172
2001 188
2002 201
2003 185
2004 191
2005 252
2006 255
2007 297
2008 280
2009 313
2010 379
2011 398
2012 412
2013 496
2014 535
2015 621
2016 591
2017 634
2018 655
2019 720
2020 764
2021 791
2022 661
2023 636
2024 307

Text availability

Article attribute

Article type

Publication date

Search Results

12,819 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Pulmonary fibrosis and/or bone marrow failure, Telomere-related, 2"
Page 1
Idiopathic pulmonary fibrosis: Current and future treatment.
Glass DS, Grossfeld D, Renna HA, Agarwala P, Spiegler P, DeLeon J, Reiss AB. Glass DS, et al. Clin Respir J. 2022 Feb;16(2):84-96. doi: 10.1111/crj.13466. Epub 2022 Jan 10. Clin Respir J. 2022. PMID: 35001525 Free PMC article. Review.
OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized by dry cough, fatigue, and progressive exertional dyspnea. ...DATA SOURCE: The data were obtained from the Randomized Controlled Trials and scientific studies pub …
OBJECTIVES: Idiopathic pulmonary fibrosis (IPF) is a chronic fibrotic lung disease characterized by dry cough, fatigue, and pr …
The Bleomycin Model of Pulmonary Fibrosis.
Liu T, De Los Santos FG, Phan SH. Liu T, et al. Methods Mol Biol. 2017;1627:27-42. doi: 10.1007/978-1-4939-7113-8_2. Methods Mol Biol. 2017. PMID: 28836192
Interstitial lung disease (ILD) comprises a large number of chronic lung disease characterized by varying degrees of inflammation and fibrosis. Mostly they are idiopathic including idiopathic pulmonary fibrosis (IPF), which is a specific disorder characterize …
Interstitial lung disease (ILD) comprises a large number of chronic lung disease characterized by varying degrees of inflammation and fib …
Inflammation and immunity in IPF pathogenesis and treatment.
Heukels P, Moor CC, von der Thüsen JH, Wijsenbeek MS, Kool M. Heukels P, et al. Respir Med. 2019 Feb;147:79-91. doi: 10.1016/j.rmed.2018.12.015. Epub 2019 Jan 9. Respir Med. 2019. PMID: 30704705 Free article. Review.
Idiopathic pulmonary fibrosis (IPF) is a progressive, and ultimately fatal, chronic interstitial lung disease characterized by enhanced extracellular matrix deposition. Repetitive alveolar epithelial injury triggers the early development of fibrosis. These in …
Idiopathic pulmonary fibrosis (IPF) is a progressive, and ultimately fatal, chronic interstitial lung disease characterized by …
Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis.
Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Finnerty JP, et al. BMC Pulm Med. 2021 Dec 11;21(1):411. doi: 10.1186/s12890-021-01783-1. BMC Pulm Med. 2021. PMID: 34895203 Free PMC article.
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fibrosis; and to compare the efficacy of anti-fibrotic therapy (grouping nintedanib and pirfenidone together) in patients with IPF versus p …
BACKGROUND: Research questions To compare the efficacy of nintedanib and pirfenidone in the treatment of progressive pulmonary fib …
Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD).
Corte TJ, Lancaster L, Swigris JJ, Maher TM, Goldin JG, Palmer SM, Suda T, Ogura T, Minnich A, Zhan X, Tirucherai GS, Elpers B, Xiao H, Watanabe H, Smith RA, Charles ED, Fischer A. Corte TJ, et al. BMJ Open Respir Res. 2021 Dec;8(1):e001026. doi: 10.1136/bmjresp-2021-001026. BMJ Open Respir Res. 2021. PMID: 34969771 Free PMC article. Clinical Trial.
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are associated with a progressive loss of lung function and a poor prognosis. ...BMS-986278, a second-generation LPA(1) antagonist, is currently …
INTRODUCTION: Idiopathic pulmonary fibrosis (IPF) and non-IPF, progressive fibrotic interstitial lung diseases (PF-ILD), are a …
Ziritaxestat, a Novel Autotaxin Inhibitor, and Lung Function in Idiopathic Pulmonary Fibrosis: The ISABELA 1 and 2 Randomized Clinical Trials.
Maher TM, Ford P, Brown KK, Costabel U, Cottin V, Danoff SK, Groenveld I, Helmer E, Jenkins RG, Milner J, Molenberghs G, Penninckx B, Randall MJ, Van Den Blink B, Fieuw A, Vandenrijn C, Rocak S, Seghers I, Shao L, Taneja A, Jentsch G, Watkins TR, Wuyts WA, Kreuter M, Verbruggen N, Prasad N, Wijsenbeek MS; ISABELA 1 and 2 Investigators. Maher TM, et al. JAMA. 2023 May 9;329(18):1567-1578. doi: 10.1001/jama.2023.5355. JAMA. 2023. PMID: 37159034 Free PMC article.
IMPORTANCE: There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF). OBJECTIVE: To assess the efficacy and safety of the autotaxin inhibitor ziritaxestat in patients with IPF. DESIGN, SETTING, AND PARTICIPANTS: The 2 …
IMPORTANCE: There is a major need for effective, well-tolerated treatments for idiopathic pulmonary fibrosis (IPF). OBJECTIVE: …
Idiopathic pulmonary fibrosis.
Koudstaal T, Wijsenbeek MS. Koudstaal T, et al. Presse Med. 2023 Sep;52(3):104166. doi: 10.1016/j.lpm.2023.104166. Epub 2023 May 6. Presse Med. 2023. PMID: 37156412 Free article. Review.
Idiopathic pulmonary fibrosis (IPF) is a progressive devastating lung disease with substantial morbidity. ...IPF affects 3 million people worldwide, with increasing incidence in older patients. The current concept of pathogenesis is that pulmonary fibrosis …
Idiopathic pulmonary fibrosis (IPF) is a progressive devastating lung disease with substantial morbidity. ...IPF affects 3 mil …
The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis?
Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. Moeller A, et al. Int J Biochem Cell Biol. 2008;40(3):362-82. doi: 10.1016/j.biocel.2007.08.011. Epub 2007 Aug 30. Int J Biochem Cell Biol. 2008. PMID: 17936056 Free PMC article. Review.
Different animal models of pulmonary fibrosis have been developed to investigate potential therapies for idiopathic pulmonary fibrosis (IPF). ...It is critical to distinguish between drugs interfering with the inflammatory and early fibrogenic response …
Different animal models of pulmonary fibrosis have been developed to investigate potential therapies for idiopathic pulmona …
Mesenchymal Stromal Cell Exosomes Ameliorate Experimental Bronchopulmonary Dysplasia and Restore Lung Function through Macrophage Immunomodulation.
Willis GR, Fernandez-Gonzalez A, Anastas J, Vitali SH, Liu X, Ericsson M, Kwong A, Mitsialis SA, Kourembanas S. Willis GR, et al. Am J Respir Crit Care Med. 2018 Jan 1;197(1):104-116. doi: 10.1164/rccm.201705-0925OC. Am J Respir Crit Care Med. 2018. PMID: 28853608 Free PMC article.
Treated animals and appropriate controls were harvested on PN7, -14, or -42 for assessment of pulmonary parameters. MEASUREMENTS AND MAIN RESULTS: HYRX-exposed mice presented with pronounced alveolar simplification, fibrosis, and pulmonary vascular remodeling …
Treated animals and appropriate controls were harvested on PN7, -14, or -42 for assessment of pulmonary parameters. MEASUREMENTS AND …
12,819 results
You have reached the last available page of results. Please see the User Guide for more information.